Contributions of Pain Interference and Affect to Patient-Reported Opioid Benefit in Chronic Pain Management

Author:

Baker Anne K.ORCID,Park Su HyounORCID,Rosser Morgan A.,Nanda Meghna,Martucci Katherine T.ORCID

Abstract

AbstractBackgroundDespite known deleterious consequences associated with long-term opioid use, many individuals with chronic pain assert opioid benefits and advocate for continued opioid use. However, relative to non-opioid using chronic pain patients, opioid-using patients typically report greater pain severity and depression. Moreover, there appears to be no significant association between pain severity or interference and perceived opioid benefit among chronic pain patients. Thus, pain reduction itself might not directly relate to patients’ perceptions of opioid benefit. Given extensive prior research revealing significant overlaps between pain and affect, it is prudent to examine contributions of affective disturbances—alongside pain-related factors—to perceived opioid benefits. In the present study, we examined the hierarchical contributions of pain interference and positive affect in predicting self-reported opioid benefit. We hypothesized that positive affect combined with pain interference would best predict opioid benefit.MethodsWe examined multisite, cross-sectional data collected from females with fibromyalgia who were using opioids long-term (n = 40) and who were not regularly using opioids but had used them acutely (< 30 days) at least once previously (n = 25). Patients completed a set of questionnaires, including the Positive and Negative Affect Schedule, the Brief Pain Inventory, and a novel measure querying perceived opioid benefit on a 0-10 Likert scale (0 = not at all, 10 = completely). We examined relationships between pain interference, positive affect, and patient-reported opioid benefit using logistic regression.ResultsAmong opioid-using patients, pain interference combined with positive affect was a better model for opioid benefit (AIC = 52.15) compared to pain interference alone (AIC = 57.80). However, among non-opioid using patients, pain interference alone was a better model for opioid benefit (AIC = 28.00) than pain interference combined with positive affect (AIC = 28.12).ConclusionsAmong patients using opioids long-term, affective factors may be primary drivers of perceived opioid benefit. Positive affect combined with pain interference modeled opioid benefit better than pain interference alone among opioid-using chronic pain patients, but not among non-opioid-using chronic pain patients. Importantly, post-hoc analyses examining the contributions of negative affect further validated the main findings; positive affect out-performed negative affect in all models. Thus, perceived opioid benefit may be a function of cumulative opioid-induced enhancements in positive affect. Based on these results, examination of factors besides pain reduction may be critical to understanding perceived opioid benefit among chronic pain patients; this understanding is essential for development of effective, opioid-sparing treatments.Key Points SummaryQuestionDoes the combination of pain and affect predict patient-reported (i.e., perceived) opioid benefit better than pain alone, and do these relationships differ between groups of opioid-using and non-opioid using individuals with chronic pain?FindingsCompared to pain interference alone, pain interference combined with positive affect was a better model of perceived opioid benefit among opioid-using chronic pain patients, but not among non-opioid using chronic pain patients, who had used opioids acutely at least once previously.MeaningAmong patients with chronic pain using opioid medications long-term, perceived opioid benefit appears to be a consequence of opioid-related enhancements in positive affect rather than pain reduction per se.

Publisher

Cold Spring Harbor Laboratory

Reference41 articles.

1. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018

2. U.S. Opioid Dispensing Rate Maps. Published March 18, 2022. Accessed August 16, 2022. https://www.cdc.gov/drugoverdose/rxrate-maps/index.html

3. Initial Opioid Prescriptions among U.S. Commercially Insured Patients, 2012–2017

4. Assistant Secretary of Public Affairs (ASPA). About the Epidemic. Accessed October 14, 2021. https://www.hhs.gov/opioids/about-the-epidemic/index.html

5. Suicide: A Silent Contributor to Opioid-Overdose Deaths

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3